You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Therapeutic Efficacies of Artesunate-Sulfadoxine-Pyrimethamine and Chloroquine-Sulfadoxine-Pyrimethamine in Vivax Malaria Pilot Studies: Relationship to Plasmodium vivax dhfr Mutations
|
|---|---|
| Published in |
Antimicrobial Agents and Chemotherapy, December 2002
|
| DOI | 10.1128/aac.46.12.3947-3953.2002 |
| Pubmed ID | |
| Authors |
Emiliana Tjitra, Joanne Baker, Sri Suprianto, Qin Cheng, Nicholas M. Anstey |
| Abstract |
Artemisinin-derivative combination therapies (ACT) are highly efficacious against multidrug-resistant Plasmodium falciparum malaria. Few efficacy data, however, are available for vivax malaria. With high rates of chloroquine (CQ) resistance in both vivax and falciparum malaria in Papua Province, Indonesia, new combination therapies are required for both species. We recently found artesunate plus sulfadoxine-pyrimethamine (ART-SP) to be highly effective (96%) in the treatment of falciparum malaria in Papua Province. Following a preliminary study of CQ plus sulfadoxine-pyrimethamine (CQ-SP) for the treatment of Plasmodium vivax infection, we used modified World Health Organization criteria to evaluate the efficacy of ART-SP for the treatment of vivax malaria in Papua. Nineteen of 22 patients treated with ART-SP could be evaluated on day 28, with no early treatment failures. Adequate clinical and parasitological responses were found by day 14 in all 20 (100%) of the patients able to be evaluated and by day 28 in 17 patients (89.5%). Fever and parasite clearance times were short, with hematological improvement observed in 70.6% of the patients. Double (at positions 58 and 117) and quadruple (at positions 57, 58, 61, and 117) mutations in the P. vivax dihydrofolate reductase (PvDHFR) were common in Papuan P. vivax isolates (46 and 18%, respectively). Treatment failure with SP-containing regimens was significantly higher with isolates with this PvDHFR quadruple mutation, which included a novel T-->M mutation at residue 61 linked to an S-->T (but not an S-->N) mutation at residue 117. ART-SP ACT resulted in a high cure rate for both major Plasmodium species in Papua, though progression of DHFR mutations in both species due to the continued use of SP monotherapy for clinically diagnosed malaria threatens the future utility of this combination. |
Mendeley readers
The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 3% |
| Indonesia | 1 | 1% |
| Germany | 1 | 1% |
| New Zealand | 1 | 1% |
| Thailand | 1 | 1% |
| Unknown | 73 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 19% |
| Student > Ph. D. Student | 11 | 14% |
| Student > Master | 10 | 13% |
| Other | 6 | 8% |
| Student > Bachelor | 5 | 6% |
| Other | 22 | 28% |
| Unknown | 10 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 33% |
| Agricultural and Biological Sciences | 15 | 19% |
| Biochemistry, Genetics and Molecular Biology | 10 | 13% |
| Immunology and Microbiology | 7 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Other | 6 | 8% |
| Unknown | 12 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 June 2012.
All research outputs
#7,535,755
of 22,992,311 outputs
Outputs from Antimicrobial Agents and Chemotherapy
#7,062
of 14,999 outputs
Outputs of similar age
#31,602
of 129,428 outputs
Outputs of similar age from Antimicrobial Agents and Chemotherapy
#29
of 74 outputs
Altmetric has tracked 22,992,311 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 14,999 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 129,428 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 74 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.